BIOAGE LABS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
BIOAGE LABS, INC. (BIOA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $8.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-05
- BIOAGE LABS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $5.90M.
- BIOAGE LABS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $2.40M.
- BIOAGE LABS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $800.00K, a 0.00% change year-over-year.
- BIOAGE LABS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- BIOAGE LABS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $800.00K, a 20.00% decline from fiscal 2024.
- BIOAGE LABS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $1.00M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $8.30M 10-Q · filed 2026-08-05 | $9.10M derived: sum of 3 quarters · filed 2026-08-05 | $9.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $2.40M 10-Q · filed 2026-05-08 | $3.20M derived: sum of 2 quarters · filed 2026-05-08 | $3.20M derived: sum of 3 quarters · filed 2026-05-08 | $3.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $800.00K derived: sum of 2 quarters · filed 2026-03-24 | $800.00K derived: sum of 3 quarters · filed 2026-08-05 | $800.00K 10-K · filed 2026-03-24 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-05 | $0.00 10-Q · filed 2025-11-06 | $800.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $800.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-08 | $800.00K derived: sum of 2 quarters · filed 2026-05-08 | $1.00M derived: sum of 3 quarters · filed 2026-05-08 | |
| 2024-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $1.00M derived: sum of 2 quarters · filed 2026-03-24 | $1.00M 10-K · filed 2026-03-24 | |
| 2024-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $200.00K 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |